Skip to main content

Table 2 Multivariate Cox proportional regression analysis for long-term mortality

From: Prognostic and diagnostic significance of copeptin in acute exacerbation of chronic obstructive pulmonary disease and acute heart failure: data from the ACE 2 study

 

Acute exacerbation of COPD (n = 84)

Acute HF

(n = 143)

 

HR (95% CI)

P

HR (95% CI)

P

Basic risk factors

 Age (per year)

n.s.

 

1.04 (1.01–1.07)

0.009

 BMI (per kg/m2)

0.90 (0.84–0.96)

0.002

0.94 (0.89–1.01)

0.032

 Mean arterial pressure (per 5 mmHg)

n.s.

 

0.99 (0.97–1.00)

0.025

 Diabetes mellitus (yes vs. no)

n.s.

 

2.56 (1.50–4.36)

0.001

 COPD (yes vs. no)

n.s.

 

1.75 (1.04–2.92)

0.035

 K+ (per mmol/l)

n.s.

 

1.88 (1.21–2.92)

0.005

 ln C-reactive protein (per log unit)

n.s.

 

1.21 (1.01–1.46)

0.042

Biomarkers adjusted for basic factors

 ln Copeptin (per log unit)

1.72 (1.21–2.45)

0.003

1.61 (1.25–2.09)

<0.001

 ln NT-proBNP (per log unit)

1.12 (0.88–1.42)

0.373

1.62 (1.27–2.06)

<0.001

 ln hs-TnT (per log unit)

1.36 (0.88–2.11)

0.164

1.32 (1.03–1.69)

0.027

Biomarkers adjusted for basic factors and each other

 ln Copeptin (per log unit)

1.79 (1.20–2.66)

0.004

1.30 (0.96–1.76)

0.091

 ln NT-proBNP (per log unit)

0.94 (0.71–1.24)

0.668

1.43 (1.07–1.89)

0.014

  1. Median follow-up time period: 813 [Q1–3356–996] days
  2. Abbreviations: BMI Body mass index, CI confidence interval, COPD chronic obstructive pulmonary disease, hs-TnT high sensitivity troponin T, HR hazard ratio, n.s not statistically significant, NT-proBNP N-terminal pro-B-type natriuretic peptide, vs. versus